Order Article Reprints

García-Molina P, Sola-Leyva A, Luque-Navarro PM, Laso A, Ríos-Marco P, Ríos A, Lanari D, Torretta A, Parisini E, López-Cara LC, et al. Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines. Pharmaceutics. 2022; 14(2):426. https://doi.org/10.3390/pharmaceutics14020426

García-Molina, Pablo, Alberto Sola-Leyva, Pilar M. Luque-Navarro, Alejandro Laso, Pablo Ríos-Marco, Antonio Ríos, Daniela Lanari, Archimede Torretta, Emilio Parisini, Luisa C. López-Cara, and et al. 2022. "Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines" Pharmaceutics 14, no. 2: 426. https://doi.org/10.3390/pharmaceutics14020426

García-Molina, P., Sola-Leyva, A., Luque-Navarro, P. M., Laso, A., Ríos-Marco, P., Ríos, A., Lanari, D., Torretta, A., Parisini, E., López-Cara, L. C., Marco, C., & Carrasco-Jiménez, M. P. (2022). Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines. Pharmaceutics, 14(2), 426. https://doi.org/10.3390/pharmaceutics14020426